《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》要点解读

Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease

  • 摘要: 近期,美国心脏协会(American Heart Association,AHA)、美国心脏病学会(American College of Cardiology,ACC)等六大学会联合发布了《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》,该指南强调了“以患者为中心,以团队为基础”的总体管理理念和重视生活方式改善对慢性冠状动脉疾病患者预后的影响,并对主要心血管不良事件风险评估及新型药物推荐等作出了新的阐述,指南内容的更新对于指导我国临床医生为慢性冠状动脉疾病患者提供高质量管理具有重要指导意义。

     

    Abstract: In July 2023, the American Heart Association (AHA), the American College of Cardiology (ACC), and four other professional societies jointly released the updated version of the AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Artery Disease. This guideline emphasizes a patient-centered and team-based approach to the overall management of chronic coronary artery disease (CCD), highlights the impact of lifestyle improvements on the prognosis of CCD patients, and provides new insights into risk assessment for major adverse cardiovascular events (MACE) and recommendations for novel medications. These updates hold significant guiding value for health care professionals in China to provide high-quality management for CCD patients.

     

/

返回文章
返回